Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy to Treat Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 - 79 years~* Documented OSA (AHI \> 10 events/hr Non rapid eye movement sleep supine)~* If treated then, current CPAP use (\>4 hrs CPAP/night for \> 2 months)~Exclusion Criteria:~* Any uncontrolled medical condition~* Any other sleep disorder (Periodic leg movement syndrome, restless legs syndrome, insomnia, etc.)~* Use of medications known to affect sleep/arousal, breathing, or muscle physiology~* Allergy to lidocaine or Afrin~* Claustrophobia~* Alcohol consumption within 24 hours of PSG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive both a sugar pill and room air during their overnight sleep studies
- Treatment (Type: ACTIVE_COMPARATOR): Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies

Based on this trial design, predict the completion outcome and termination type (if applicable).